B2BROKER-GROUP
26.8.2021 15:04:33 CEST | Business Wire | Press release
B2Broker Group is pleased to officially announce the launch of its venture fund, B2Broker VC. B2Broker VC is led by a team that is one of the most successful and fast-growing financial technology groups with in-depth expertise in sectors ranging from IT development to capital management. The venture fund will enable the investment in, and nurture of external projects that are of interest such as new fintech startups and payment systems, and will create synergies for the group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005497/en/
First Ventures
Back in 2017, like many other tech industry giants, B2Broker Group started working on its own internal corporate venture fund. This was focused on the development of a number of specific projects. Since then, the capitalisation of the group’s fund has grown steadily and now includes a number of projects in which the company has invested over $15 million so far. This is an exciting project which has enabled the development of a modern financial and technological ecosystem on the basis of the B2Broker group of companies.
Of particular focus is the launch of B2BinPay in 2017, a payment system which has become one of the most modern and technologically progressive platforms in the world, B2BX , a platform for the trading of digital assets which is licenced in the EU, Eqwire, a digital banking service, and last but not least, the group’s most expensive and complex project, B2Prime, which is an integrated liquidity provider with licences in different jurisdictions, including Europe and CIS.
External Projects
With the experience acquired on these internal projects and the business-processes that have been developed, B2Broker VC has also started investing in external projects. One of the most noteworthy of these is the innovative Coinsbuy, a project designed to cater for the growing demand for buying crypto using a credit or debit card. This will be a complementary project to B2Broker’s ecosystem.
Throughout this process, B2Broker VC identified the most interesting sectors such as fintech, IT development and automation, as well as startups offering products for the brokerage market.
Procedures and Stages
The most important aspect that the group seeks in its partners is conscientiousness, a clear vision and a good understanding of the market. B2Broker VC considers all potential recipients of investments as long-term strategic partners who in partnership, will move towards global leadership in the various market sectors.
B2Broker VC always finds the most convenient way of investment and cooperation both through equity holding and via convertible loans, which make the terms of cooperation as flexible as possible.
Companies who wish to apply for funding follow a step-by-step procedure starting with the preparation of an application and documents. This is followed by a product performance evaluation, follow-up questions and a series of meetings and evaluations before the final decision is made. After the signing of various documents and agreements, the first tranche of investment will be released after a process which takes between 2-6 months.
The kind of projects that are of interest to B2Broker VC are ones that match the group’s goals and business model. These include:
● Fintech development: Products and services for Forex, securities, derivatives, CFD and crypto markets.
● IT development: Development of payment systems, trading and brokerage platforms, risk management systems, analytical systems.
We are particularly interested in companies who have Bridges Technology and plugins for MT4/5, Trading Platforms for FX/CFD trading and those who have built trading platforms for Crypto Perpetual Futures, Crypto Spot trading and Securities trading on Exchanges. We are also looking for HUB and liquidity aggregation solutions and technology for market making on crypto exchanges.
● Automation: Products in the field of automation of external systems and process automation services.
● Products/services suitable for B2Broker's ecosystem such as KYC solutions, marketing services, products and services for the brokerage market.
Companies that end up working with the B2Broker Group will be handed the keys to the development of a young company that includes both financial assistance and access to the group’s infrastructure, its offices, and development teams, as well as top financial and marketing expertise.
Applications
B2Broker VC carefully considers each application received and investigates the possible mechanisms of cooperation, regardless of the size of the company and entrepreneurial experience among the founders.
To submit your application and become a global leader with B2Broker VC email us at vc@b2broker.com or visit our website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005497/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
